Compare ELE & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELE | PHAR |
|---|---|---|
| Founded | N/A | 1988 |
| Country | Canada | Netherlands |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2025 | 2020 |
| Metric | ELE | PHAR |
|---|---|---|
| Price | $21.29 | $11.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $32.50 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 274.1K | 21.9K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.18% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $109.25 | $10.04 |
| Revenue Next Year | $16.14 | $2.51 |
| P/E Ratio | ★ $255.64 | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.01 | $9.62 |
| 52 Week High | $26.96 | $21.34 |
| Indicator | ELE | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 59.89 | 44.74 |
| Support Level | $20.87 | $9.62 |
| Resistance Level | $22.45 | $13.51 |
| Average True Range (ATR) | 0.78 | 0.35 |
| MACD | -0.22 | -0.00 |
| Stochastic Oscillator | 47.86 | 27.18 |
Elemental Royalty Corp is engaged in exploration discovery, royalty generation, royalty acquisition, and strategic investments. It is the result of the strategic merger of Elemental Altus Royalties and EMX Royalty Corporation together creating a mid-tier gold-focused royalty company with the scale, diversification, and cash flow. Geographically, the company generates revenue from North America, South America, Europe, Australia and Africa.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.